AM-Pharma gathers €116M for PhIII program on kidney drug Pfizer passed on
Back in 2015, Pfizer put a spotlight on Dutch biotech AM-Pharma and its drug candidate for sepsis-associated acute kidney injury, anteing up $87.5 million for a minority stake in addition to an option to gobble the whole operation up. The Phase II trial that the giant partner had bet on ended up delivering a mixed win, and Pfizer walked away from the deal citing “internal strategic reasons” — leaving the small player on its own to pull off a large Phase III study and ponder commercialization.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters